Slide 1: Ipca Laboratories Ltd. Corporate Presentation
Ipca Laboratories Ltd. Corporate Presentation June 2024
Slide 2: About Us
About Us Incorporation Consolidated Income Export to >16,000 26 6 70+ FY 2023-24 100+ Employees Manufacturing R&D years ₹7,830 Crs countries with facilities labs US$950 Mn ~44% income share 2
Slide 3: Our Values
Our Values Adhere to Ensure safety Comply with Value Facilitate good standards comes first ethics & standards people business practices 3
Slide 4: Five Years' Highlights - Standalone
Five Years’ Highlights Standalone 7000 ₹6,277.75 ₹5,925.81 ($757.82) ₹5,491.22 ($738.69) 6000 ₹5,201.40 ($699.20) ($737.38) 5000 ₹4,432.12 ($625.65) ₹3,570.05 4000 ₹3,282.39 ($430.96) ₹2,484.21 ₹2,983.09 ($409.17) ($333.94) ($400.58) 3000 ₹2,288.37 ($323.03) 2000 ₹2,643.42 ₹2,707.70 ₹2,717.19 ₹2,508
Slide 5: Five Years' Highlights - Consolidated
Five Years’ Highlights Consolidated ₹7,829.81 8000 ($945.17) ₹6,369.94 7000 ($794.06) ₹5,896.36 ₹5,482.83 ($791.78) 6000 ($737.03) ₹4,715.71 5000 ($665.68) ₹3,391.06 ₹4090.77 4000 ₹3,077.75 ($422.72) ₹2,963.06 ($493.82) ($413.29) ₹2,327.88 ($398.31) 3000 ($328.61) ₹3,739.04 ($451.35) 2000 ₹2,818.61
Slide 6: Manufacturing Facilities - Formulations
Manufacturing Facilities Formulations
Slide 7: Manufacturing Facilities (Formulations)
Manufacturing Facilities (Formulations) Baddi# Dehradun Kandla (2 facilities) New Delhi (ß-lactum) Jorethang (2 facilities) Ratlam Capital Corporate Office Ghaziabad# Formulations R&D SEZ - Pithampur Mumbai Mumbai Piparia (Biotech + R&D) Pithampur Athal (Biotech) Pisgah Labs Tarapur Goa# (North Caro
Slide 8: Manufacturing Facilities (Formulations)
Manufacturing Facilities (Formulations) Location Dosage Form Inspections / Approvals by Agencies of Athal (Dadra & Nagar Haveli) Tablets & Capsules Australia, Bahrain, Cambodia, Canada, Colombia, EU, GCC/GHC, Ghana, India, Kenya, Malawi, Oman, Russia, Tanzania, Uganda, UK, Ukraine, WHO, Yemen Ratlam
Slide 9: Manufacturing Facilities - APIs
Manufacturing Facilities Active Pharmaceutical Ingredients (APIs)
Slide 10: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) Onyx Scientific (Sunderland, UK) (APIs + R&D) Ratlam New Delhi Dewas Nandesari Capital Baroda Corporate Office Ranu APIs R&D Overseas Indore Ankleshwar Mumbai Hingni Pithampur# Mumbai (R&D) Chh. Sambhajinagar (2 Facilities) Pisgah Labs Tarapur Mahad Vizag* Nellore* (N
Slide 11: Manufacturing Facilities (APIs)
Manufacturing Facilities (APIs) Location Inspections / Approvals by Agencies of Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO Indore (Madhya Pradesh) India, EU, WHO Dewas (Madhya Pradesh) India Ankleshwar (Gujarat) EU, India, Jap
Slide 12: Revenue Break-up
Revenue Break-up 2022-23 & 2023-24
Slide 13: Revenue Break-up (Standalone 2023-24)
Revenue Break-up (Standalone 2023-24) Total Total Revenue Exports Domestic 2023-24 2023-24 2023-24 2023-24 9% 20% 43% 46% 80% 57% 54% 91% APIs Formulations Export Domestic APIs Formulations APIs Formulations Formulations APIs Domestic Exports Formulations APIs Formulations APIs 13
Slide 14: Revenue Break-up (Standalone)
Revenue Break-up (Standalone) 2023-24 2022-23 ₹Crs Domestic Exports Total Domestic Exports Total Growth Branded Formulations 3097.16 526.70 3623.86 2760.71 504.79 3265.50 11.0% Generic / Institution / Tender Formulations - 1248.62 1248.62 - 1134.40 1134.40 10.1% Total Formulations 3097.16 1775.32 48
Slide 15: Financials
Financials FY 2022-23 & FY 2023-24
Slide 16: Financials Standalone
Financials Standalone FY 2023-24 FY 2022-23 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 6277.75 758 5925.81 739 6% EBIDT 1189.54 144 942.86 118 26% EBIDT % 19.29% - 16.22% - - PBT # 955.52 115 750.49 94 27% PBT % 15.5% - 12.91% - - PAT # 530.41 64 505.70 63 5% PAT % 8.60% - 8.70% - - # After forex
Slide 17: Financials Standalone - Profitability
Financials Standalone Profitability FY 2023-24 FY 2022-23 19.8% 44.5% 26.9% 23.0% 42.9% 39.4% PAT PBIDT PAT PBIDT 8.60% 19.29% 8.70% 16.22% 35.7% 34.1% 33.6% PBT PBT 15.50% PBIDT PBT PAT 12.91% PBIDT PBT PAT 17
Slide 18: Financials Standalone - Business Characteristics
Financials Standalone Business Characteristics FY 2023-24 FY 2022-23 Return on Capital Employed % (PBIT / Capital Employed) 14.75% 11.59% Return on Net Worth % (PAT / Net Worth) 10.46% 8.60% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.33 2.28 Capital Employed Turnover Ratio (Total
Slide 19: Financials Standalone - Growth
Financials Standalone Growth FY 2023-24 FY 2022-23 Net Total Income 5.9% 7.9% Domestic Sales 8.9% 9.3% Export Sales 2.4% 5.4% PBIDT 26.2% -16.3% PBT 27.3% -30.1% Net Profit 4.9% -41.2% 19
Slide 20: Financials Standalone - Q1 FY25
Financials Standalone Q1 FY25 Q1 FY24 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 1581.25 190 1529.50 186 3% EBIDT 348.44 42 284.28 35 23% EBIDT % 22.25% - 19.13% - - PBT # 287.89 35 249.78 30 15% PBT % 18.4% - 16.81% - - PAT # 204.13 24 166.58 20 23% PAT % 13.03% - 11.21% - - # After forex gain o
Slide 21: Financials Consolidated
Financials Consolidated FY 2023-24 FY 2022-23 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 7829.81 945 6369.94 794 23% EBIDT 1288.21 156 958.28 119 34% EBIDT % 16.72% - 15.35% - - PBT # 842.67 102 745.29 93 13% PBT % 10.94% - 11.94% - - PAT # 547.35 66 471.32 59 16% PAT % 7.10% - 7.55% - - # After
Slide 22: Financials Consolidated - Business Characteristics
Financials Consolidated Business Characteristics FY 2023-24 FY 2022-23 Return on Capital Employed % (PBIT / Capital Employed) 16.30% 15.21% Return on Net Worth % (PAT / Net Worth) 11.47% 10.71% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.12 2.92 Capital Employed Turnover Ratio (To
Slide 23: Financials Consolidated - Growth
Financials Consolidated Growth FY 2023-24 FY 2022-23 Net Total Income 22.9% 8.0% Domestic Sales 9.4% 9.5% Export Sales 37.3% 5.7% PBIDT 34.43% -19.4% PBT 13.07% -34.4% Net Profit 9.2% -46.7% 23
Slide 24: Financials Consolidated - Quarterly
Financials Consolidated Q1 FY 25 Q1 FY 24 ₹Crs US$ Mn ₹Crs US$ Mn % Growth Total Income 2113.24 253 1630.06 198 30% EBIDT 387.49 46 294.33 36 32% EBIDT % 18.52% - 18.57% - - PBT # 290.39 35 251.82 31 15% PBT % 13.88% - 15.89% - - PAT # 192.24 23 162.82 20 18% PAT % 9.19% - 10.27% - - # After forex g
Slide 25: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups Therapeutic Segment 2023-24 Domestic 2022-23 2023-24 Export 2022-23 Non Steroidal Anti-Inflammatory Drugs (NSAID) 49 52% 52% Non Steroidal Anti-Inflammatory Drugs (NSAID) 49 31% 28% Cardiovasculars & Anti-Diabetics 17% 16% Cardiovasculars & An
Slide 26: Branded Formulations - Domestic
Branded Formulations Domestic
Slide 27: Branded Formulations Domestic
Branded Formulations Domestic All India Rank IQVIA 21 Market leaders in Therapy Focused Over 4000 Rheumatoid Arthritis 16th (MAT June’24) Marketing Divisions Wholesalers & Anti-malarials 24 Depots & Field Strength 5 brands among 1 C&F agent (PSR / BA)-6476 top 300 brands (Zerodol-SP, Zerodol-P, HCQS
Slide 28: Branded Formulations Domestic Sales
Branded Formulations Domestic 4000 ₹3097.16 ($374 Mn) 3000 ₹2760.71 ₹2508.27 ($344 Mn) ($337 Mn) 2500 ₹1981.67 ($266 Mn) 2000 1500 1000 500 2023-24 0 2020-21 2021-22 2020-21 2021-22 2022-23 2023-24 2022-23 Figures in Crores. Sales 28
Slide 29: Future Growth Drivers - Domestic Branded Formulations
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. Strong brand building with focused promotion. In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies to identify n
Slide 30: International Business
International Business
Slide 31: International Business
International Business Recognised Field-force to promote brands Five Star Export in more than Registrations in House 30 countries 59 countries Products of the company 43% sales Marketing offices in are now exported to over From exports 12 countries 100 countries across the globe 31
Slide 32: International Business Sales
International Business 3000 ₹2717.19 ₹2643.42 ₹2707.70 ($365 Mn) ₹2508.13 ($327 Mn) ($337 Mn) ($330 Mn) 2500 2000 1500 1000 500 2023-24 0 2020-21 2021-22 2020-21 2021-22 2022-23 2023-24 2022-23 Figures in Crores. Sales 32
Slide 33: Continent-wise Exports 2023-24
International Business Continent-wise Exports 2023-24 (₹Crs) Continent Formulations APIs Total % Contribution Europe 468.73 315.26 783.99 29% Africa 477.76 42.69 520.45 19% Americas 184.88 255.49 440.37 16% Asia 134.18 267.10 401.28 15% CIS 206.76 45.89 252.65 9% Australasia 303.01 5.95 308.96 11% T
Slide 34: International Formulations
International Formulations
Slide 35: International Formulations Sales
International Formulations ₹1639.19 ₹1775.32 1800 ₹1597.19 ($214 Mn) ($204 Mn) ($215 Mn) ₹1486.74 1600 ($200 Mn) 1400 1200 1000 800 600 400 200 2023-24 0 2020-21 2021-22 2020-21 2021-22 2022-23 2023-24 2022-23 Figures in Crores. Sales 35
Slide 36: International Branded Formulations
International Branded Formulations
Slide 37: International Branded Formulations Sales
International Branded Formulations ₹526.70 530 ₹504.79 ($64 Mn) ($63 Mn) 510 490 470 450 430 ₹415.99 ₹403.42 ($56 Mn) ($54 Mn) 410 390 370 350 2023-24 330 2020-21 2021-22 2020-21 2021-22 2022-23 2023-24 2022-23 Figures in Crores. Sales 37
Slide 38: Future Growth Drivers - International Branded Formulations
International Branded Formulations Future Growth Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments. Geographical expansion in covered countries through additional field force. Expansion in business lines - Institutions and Distributors. Introduction of new
Slide 39: International Generics / Institution / Tender
International Generics / Institution / Tender
Slide 40: International Generics / Institution / Tender
International Generics / Institution / Tender Products Products Under 1400 ₹1248.62 Country Registered Registration ₹1193.77 ($151 Mn) ($160 Mn) ₹1134.40 United Kingdom 1200 ₹1070.75 ($141 Mn) 53 2 ($144 Mn) / Europe 1000 Australia / 73 3 New Zealand 800 South Africa 53 10 600 United States / 45 16
Slide 41: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Future G
Slide 42: International Active Pharmaceutical Ingredients (APIs)
International Active Pharmaceutical Ingredients (APIs)
Slide 43: International APIs Sales
International APIs ₹1120.00 1200 ($151 Mn) ₹1021.39 ₹1004.23 ($137 Mn) ($125 Mn) 1000 ₹932.38 ($113 Mn) 800 600 400 200 2023-24 0 2020-21 2021-22 2020-21 2021-22 2022-23 2023-24 2022-23 Figures in Crores. Sales 43
Slide 44: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 1 1 Alendronate Sodium - - - 2 2 Allopurinol - - CEP 3 Amlodipine Besylate - - - - 3 4 Amlodipine Besylate (AK4 Proce
Slide 45: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 11 12 Benzarone - - - - - 12 13 Benzbromarone - - - - - 13 14 Bisoprolol Fumarate - - - 14 15 Bupropion Hydrochloride
Slide 46: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 20 23 Citalopram HBR - - - - - 21 24 Donepezil Hydrochloride Monohydrate - - - - - - 22 25 Dihydroartemesinin - - - -
Slide 47: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 33 Furosemide - CEP 28 34 Furosemide (Veterinary) - - - - - - 29 35 Glimepiride - - - 36 Hydrochlorothiazide (Process
Slide 48: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 44 Losartan Potassium (LB3 Process) - - - - - 36 45 Losartan Potassium (LB4 Process) - - - - - 46 Losartan Potassium
Slide 49: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 43 55 Metoclopramide Base - - - - - 56 Metoclopramide HCl - - - - CEP 44 57 Metoclopramide HCl (M Process) - - - - 45
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 52 66 Ondansetron Hydrochloride - - CEP 53 67 Paroxetine HCl - - - - CEP 54 68 Piperaquine Phosphate - - - - - 55 69
Slide 51: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 63 77 Quetiapine Fumarate - - CEP 64 78 Quetiapine Fumarate (QT5 Process) - - - - - 65 79 Ractopamine HCl - - - - 66
Slide 52: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on June’24 (Based on DMFs Sr. No.) API DMF Canada- Japan- Sr. No. Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM 72 88 Triamterene - - - - 89 Trimethoprim - - - CEP 73 90 Trimethoprim (T Process) - - - - - 91 Trimethoprim (T4 Proc
Slide 53: International APIs Future Growth Drivers
International APIs Consolidate API business of Sartans across the globe. Future Growth Drivers Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 countries is well laid down platform to introduce new p
Slide 54: Research & Development - APIs & Formulations
Research & Development APIs & Formulations
Slide 55: R&D Spending - APIs & Formulations
Research & Development APIs & Formulations Year ₹Crs % to Sales 180 ₹161.50 4.50% ₹146.46 ₹156.49 2.64% 2019-20 101.04 2.35% 160 2.63% 2.71% 4.00% ₹126.67 140 2.49% 3.50% 2020-21 126.67 2.49% 120 ₹101.04 3.00% 2.35% 2021-22 141.46 2.63% 100 2.50% 2022-23 156.49 2.71% 80 2.00% 60 1.50% 2023-24 161.50
Slide 56: Research & Development - APIs & Formulations
Research & Development APIs & Formulations Current scientist manpower of 590+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Biotech / fermentation rese
Slide 57: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialization” Single-use CGMP Bio-manufacturing Facility (DS+DP+QC) is being established and to be ready by De
Slide 58: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer and Anti-inflammatory mAbs Stage of Development 7 Monoclonal antibodies (mAbs) at various Molecules Development Pre-clinical Clinical Trials MAA / Launch stages of the development UK / HC / IN / EU Target markets India, UK,HC, EU, ROW followed b
Slide 59: Thank You
Thank You No part of this corporate presentation may be re-produced, quoted or circulated without prior approval of Ipca Laboratories Limited. This presentation may include forward looking statements based on our current business expectations. Our actual results may differ from what is projected in